Press Releases July 23, 2026 05:00 PM

Krystal Biotech to Report Second Quarter 2026 Financial Results on August 3, 2026

Krystal Biotech schedules Q2 2026 earnings release and conference call for August 3

By Derek Hwang
Share
Twitter Reddit Facebook LinkedIn
KRYS

Krystal Biotech, a Nasdaq-listed biotechnology firm, announced it will report its second quarter 2026 financial results on August 3, 2026, before U.S. market open and will host a live webcast conference call to discuss the results and provide a business update.

Krystal Biotech to Report Second Quarter 2026 Financial Results on August 3, 2026
KRYS
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Krystal Biotech is a commercial-stage biotech company focused on genetic medicines targeting diseases with high unmet needs.
  • The company's first approved product, VYJUVEK®, is a redosable gene therapy approved in the US, Europe, and Japan for dystrophic epidermolysis bullosa.
  • The company is advancing a pipeline of preclinical and clinical genetic medicine candidates.

PITTSBURGH, July 23, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that it will report its second quarter 2026 financial results on Monday, August 3, 2026, prior to the open of U.S. markets.

The Company’s management will also host a conference call and webcast at 8:30 am ET on Monday, August 3, 2026, to discuss the financial results and provide a business update.

Investors and the general public can access the live webcast at: https://www.webcaster5.com/Webcast/Page/3018/54300.

For those unable to listen to the live webcast, a replay will be available for at least 30 days on the Investors section of the Company’s website at www.krystalbio.com.

About Krystal Biotech, Inc.
Krystal Biotech, Inc. (NASDAQ: KRYS) is a fully integrated, commercial-stage, global biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK®, the Company’s first commercial product, is the first-ever redosable gene therapy and the first genetic medicine approved in the United States, Europe, and Japan for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. Visit www.krystalbio.com to learn more or follow us on LinkedIn and X.

CONTACT
Investors and Media:                                                             
Stéphane Paquette, PhD
Krystal Biotech
[email protected]                                    


Risks

  • Financial results could be below market expectations impacting stock price.
  • Risks inherent in clinical and preclinical development success affect future product pipeline.
  • Regulatory and commercialization risks exist for both current and future gene therapy products.

More from Press Releases

Sachem Capital Reports Third Quarter 2026 Results Nov 16, 2026 Inter&Co Delivers Record 3Q26 Net Income of US$76.1 Million, With Strong Growth, Higher Margin and Better Efficiency Nov 12, 2026 Super League to Report Third Quarter 2026 Financial Results on Monday, November 16, 2026 Nov 12, 2026 UroGen Reports $68.0 Million of ZUSDURI Revenue and Provides Third Quarter 2026 Financial Results and Highlights Nov 4, 2026 BioVie Announces Pricing of $4.74 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules Nov 4, 2026